[PDF][PDF] Aluminium toxicosis: a review of toxic actions and effects
IO Igbokwe, E Igwenagu… - Interdisciplinary …, 2019 - intapi.sciendo.com
Aluminium (Al) is frequently accessible to animal and human populations to the extent that
intoxications may occur. Intake of Al is by inhalation of aerosols or particles, ingestion of …
intoxications may occur. Intake of Al is by inhalation of aerosols or particles, ingestion of …
Aluminium as a risk factor in Alzheimer's disease, with emphasis on drinking water
TP Flaten - Brain research bulletin, 2001 - Elsevier
Aluminium (Al) is clearly a powerful neurotoxicant. Considerable evidence exists that Al may
play a role in the aetiology or pathogenesis of Alzheimer's disease (AD), but whether the link …
play a role in the aetiology or pathogenesis of Alzheimer's disease (AD), but whether the link …
Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease
SM de la Monte - Current Alzheimer Research, 2012 - ingentaconnect.com
Alzheimer's disease [AD] is the most common cause of dementia in North America. Despite
30+ years of intense investigation, the field lacks consensus regarding the etiology and …
30+ years of intense investigation, the field lacks consensus regarding the etiology and …
Aluminum and Alzheimer's disease: after a century of controversy, is there a plausible link?
L Tomljenovic - Journal of Alzheimer's Disease, 2011 - content.iospress.com
The brain is a highly compartmentalized organ exceptionally susceptible to accumulation of
metabolic errors. Alzheimer's disease (AD) is the most prevalent neurodegenerative disease …
metabolic errors. Alzheimer's disease (AD) is the most prevalent neurodegenerative disease …
Challenges and opportunities of deferoxamine delivery for treatment of Alzheimer's disease, Parkinson's disease, and intracerebral hemorrhage
AC Farr, MP Xiong - Molecular pharmaceutics, 2020 - ACS Publications
Deferoxamine mesylate (DFO) is an FDA-approved, hexadentate iron chelator routinely
used to alleviate systemic iron burden in thalassemia major and sickle cell patients. Iron …
used to alleviate systemic iron burden in thalassemia major and sickle cell patients. Iron …
Aluminium in Alzheimer's disease: are we still at a crossroad?
Aluminium, an environmentally abundant non-redox trivalent cation has long been
implicated in the pathogenesis of Alzheimer's disease (AD). However, the definite …
implicated in the pathogenesis of Alzheimer's disease (AD). However, the definite …
Aluminum as a toxicant
A Becaria, A Campbell… - Toxicology and industrial …, 2002 - journals.sagepub.com
Although aluminum is the most abundant metal in nature, it has no known biological
function. However, it is known that there is a causal role for aluminum in dialysis …
function. However, it is known that there is a causal role for aluminum in dialysis …
Understanding aspects of Aluminum exposure in a lzheimer's disease development
R Kandimalla, J Vallamkondu, EB Corgiat… - Brain …, 2016 - Wiley Online Library
Aluminum is a ubiquitously abundant nonessential element. Aluminum has been associated
with neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral …
with neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral …
The significance of environmental factors in the etiology of Alzheimer's disease
WB Grant, A Campbell, RF Itzhaki… - Journal of Alzheimer's …, 2002 - content.iospress.com
The proposition that environmental agents, such as diet, aluminum, and viruses, are as
important as genetic factors in the etiology of Alzheimer's disease (AD) was advanced by the …
important as genetic factors in the etiology of Alzheimer's disease (AD) was advanced by the …
Magnetic resonance spectroscopy in AD
MJ Valenzuela, P Sachdev - Neurology, 2001 - AAN Enterprises
Proton MR spectroscopy (MRS) studies have found both decreased N-acetylaspartate (NAA)
and increased myo-inositol in the occipital, temporal, parietal, and frontal regions of patients …
and increased myo-inositol in the occipital, temporal, parietal, and frontal regions of patients …